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Abstract
YM155, which inhibits the anti-apoptotic protein survivin, is known to exert anti-tumor effects in various cancers, including
prostate and lung cancer. However, there are few reports describing the inhibitory effect of YM155 on human pancreatic
cancers that highly express survivin. Here, we tested the effects of YM155 on a variety of cancer cell lines, including
pancreatic cancer cells. We found that YM155 exerts an anti-proliferative effect in pancreatic cancer cells, inducing cell death
through suppression of XIAP (X-linked inhibitor of apoptosis) as well as survivin without affecting the anti-apoptotic
proteins Bcl-xL or Mcl-1. YM155 also inhibited tumor growth in vivo, reducing the size of pancreatic cancer cell line
MIAPaCa-2 xenografts by 77.1% on day 31. Western blot analyses further showed that YM155 downregulated
phosphoinoside 3-kinase (PI3K) expression and reduced the levels of phosphorylated (activated) extracellular signal-
regulated kinase (ERK) and STAT3 (signal transducer and activator of transcription 3) in PANC-1 cells. Interestingly, we also
found that YM155 downregulated the epidermal growth factor receptor (EGFR) in various cancer cell lines and induced the
EGFR phosphorylation and ubiquitination of EGFR in PANC-1 cells. YM155 also modestly promoted the ubiquitination of
survivin and XIAP. Therefore, YM155 acts through modulation of EGFR and survivin expression to subsequently reduce
survival. We suggest that YM155 has potential as a therapeutic agent in the treatment of pancreatic cancer.
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Introduction
Pancreatic cancer is a highly aggressive malignant disease.
Despite therapeutic advances, the prognosis of patients with
pancreatic cancer is extremely poor. The poor prognosis of
pancreatic cancer patients is attributable to the tendency of this
cancer to respond poorly to chemotherapy. Although the
nucleoside analog gemcitabine is currently the standard chemo-
therapeutic agent used in pancreatic cancer, its survival benefit is
unsatisfactory and novel therapeutic agents are desperately needed
[1].
The overexpression of survivin, the smallest member (16.5 kDa)
of the inhibitor of apoptosis (IAP) family of proteins, has been
reported to be important in the development and progression of
pancreatic cancer [2,3]. Survivin contains a single baculovirus IAP
repeat (BIR) and interacts with chromosomal passenger proteins,
NES (nestin), aurora kinase B, SMAC/DIABLO, CDK1 (cyclin-
dependent kinase 1), PKA (protein kinase A), XIAP, and heat
shock protein (HSP)-90 [2,3]. Survivin localizes to the cytoplasm,
mitochondria and nuclei, and is expressed ubiquitously in
embryonic stages but is undetectable in normal terminally-
differentiated adult tissues [2,3]. Pathologically, survivin is over-
expressed in many human cancers, including pancreatic cancer
[2,3]. As survivin is highly expressed in pancreatic tumor tissues,
but not in normal pancreatic tissues, it is an attractive target for
drug development against pancreatic cancer [4].
YM155, a small molecule inhibitor of survivin developed by
Astellas Pharma, Inc. that is currently undergoing clinical trials,
suppresses transactivation of survivin through direct binding to its
promoter [5]. YM155 has been examined in various cancer cell
types, including melanomas and lymphomas, as well as prostate,
lung, and breast cancers [6]. Xenograft models have also shown
the anticancer efficacy of YM155 in combination with platinum
compounds [7] or docetaxel [8] as well as in monotherapy [9].
The epidermal growth factor receptor (EGFR), which is
overexpressed in various cancers and has been investigated in
relation to cancer prognosis [10,11,12], is known to be an
important factor in pancreatic cancer progression [13]. The
binding of a ligand to EGFR promotes conformational changes
that induce receptor dimerization, resulting in tyrosine autopho-
sphorylation and receptor activation. The activated EGFR signals
through phosphorylated tyrosine residues to stimulate multiple
pathways, including mitogen-activated protein kinase (MAPK),
phosphatidylinositol 3-kinase (PI3K)/Akt, signal transducers and
activators of transcription (STAT), phospholipase C, and Src/focal
adhesion kinase (Src/FAK) pathways. Activation of EGFR
signaling plays an important role in fostering proliferation and
survival; conversely, interruption of EGFR promotes apoptosis.
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veloped for the treatment of pancreatic cancer.
YM155 has shown antitumor activity in pancreatic cancer cell
lines [14]. Moreover, in breast cancer cells, survivin expression has
been reported to be regulated by EGFR via the PI3K/AKT
pathway, another important pathway in pancreatic cancers [15].
Therefore, it seems possible to have the effect of YM155 on EGFR
and its downstream signaling in pancreatic cancer cells because
survivin is regulated with EGFR.
In this study, we evaluated the anticancer effects of YM155 in
pancreatic cancer cell lines and xenografts. In addition, we
investigated the effect of YM155 on EGFR, PI3K, ERK, and
STAT3 expression to determine whether YM155 affects the
EGFR/PI3K/STAT3 pathways. We also investigated the effect of
YM155 on the expression of other members of the IAP family
related with anti-apoptotic and pro-apoptotic proteins in pancre-
atic cancer cell lines.
Results
Pancreatic cancer cells are sensitive to YM155
To investigate the anti-proliferative capacity of YM155 in
various cancer cell lines, we measured IC50 values for YM155 in
pancreatic, gastric, and colorectal cancer cells (Table 1 and Table
S1). The IC50 values for YM155 in pancreatic, gastric, and
colorectal cancer cell lines were 3.7–30.3, 1.4–140.8, and 8.7–
370.0 nM, respectively. Thus, YM155 is effective in pancreatic,
gastric, and colorectal cancer cells.
To determine the effect of the survivin inhibitor YM155 on the
expression of survivin and XIAP, another member of the IAP
family, we performed Western blotting in pancreatic and gastric
cancer cell lines (Fig. 1A and Fig. S1). At high concentrations,
YM155 significantly decreased the expression of survivin in
PANC-1, MIAPaCa-2, BxPC-3, KATOIII, and MKN45 cell
lines. YM155 was notably more potent in PANC-1 cells, where it
decreased expression of survivin at a low concentration (10 nM).
YM155 also inhibited the expression of XIAP in pancreatic and
gastric cancer cell lines, except for MKN45 cells; in these cells,
YM155 had no discernable effect on XIAP levels. In line with
previous observations [9,16], YM155 showed little effect on the
expression of the IAPs, cIAP1 and cIAP2, in pancreatic cancer cell
lines (Fig. S2).
To determine whether YM155-induced downregulation of
XIAP expression is due to reduced expression of survivin, we
knocked down survivin in PANC-1 with siRNA (siSurvivin) and
assessed XIAP expression by Western blotting (Fig. 1B). The level
of XIAP protein was decreased to a greater extent after exposure
to 10 nM YM155 than in cells transfected with siSurvivin,
suggesting that the YM155-induced decrease in XIAP levels does
not occur via downregulation of survivin. Survivin has been
reported to have binding sites for XIAP [2]. To examine the effect
of YM155 on survivin–XIAP interactions, we immunoprecipitated
survivin and then probed immunoprecipitates by Western blotting
with an antibody against XIAP (Fig. S3). Treatment of PANC-1
cells with 100 nM YM155 for 6 hours had no effect on the levels
of survivin or XIAP, but did slightly inhibit the interaction of
survivin with XIAP, suggesting that YM155 affects the assembly of
the survivin–XIAP complex to some extent.
We also investigated the effects of YM155 on the expression of
anti-apoptotic and pro-apoptotic proteins in pancreatic cancer cell
lines (Fig. 1C). There was no change in Bcl-xL or Mcl-1 levels after
treatment with YM155. YM155 induced a concentration-de-
pendent decrease in Bid, p-Bad, and Bad levels in most pancreatic
cancer cell lines; the exception was Bid, which was unaffected in
BxPC-3 cells.
YM155 induces downregulation of PI3K, p-ERK, and p-
STAT3
Because YM155 suppressed XIAP expression, we examined
whether YM155 affected the expression of other signaling
components in pancreatic cancer cells. Treatment of HER2-
overexpressing MCF7 cells with the PI3K inhibitor LY294002 or
ERK1/2 inhibitor U0126 has been reported to downregulate
survivin [17]. A STAT3 inhibitor has also been reported to
suppress survivin expression [18]. On the basis of these reports, we
investigated the effects of YM155 on PI3K, ERK, and STAT3 in
PANC-1 cells (Fig. 2), which we had found to be the most YM155-
sensitive of the pancreatic cell lines tested. Treatment of these cells
with YM155 at concentrations of 10 nM and above decreased
PI3K (Fig. 2A), p-ERK (Fig. 2B), and p-STAT3 (Fig. 2C) levels
compared with those in siSurvivin-treated cells. The PI3K
inhibitor LY294002 and MEK1/2 inhibitor AZD6244 were used
as controls to analyze the levels of PI3K, phosphorylated ERK and
survivin. We also examined the effects of YM155 on the
expression of the PI3K family members p110a, p110b, class III,
p85, and p-p85 in PANC-1, MIAPaCa-2, and BxPC-3 cells, and
found that all were reduced by 100 nM YM155 in all three cell
lines (Fig. S4). Moreover, phosphorylation of Akt, which is
a downstream effector of PI3K, was also reduced by YM155
(100 nM) in these pancreatic cancer cell lines. Akt is known to
promote cell survival through phosphorylation of Bad [19,20].
Therefore, a reduction in the phosphorylated form of Akt induces
a decrease in p-Bad, as shown in Figure 1C, resulting in cell death.
YM155 downregulates EGFR expression
Because YM155 downregulates PI3K, p-ERK, and p-STAT3,
which are downstream mediators of EGFR signaling [21,22,23],
we analyzed whether YM155 affects the expression of EGFR
(Fig. 3). As expected, treatment with EGF increased EGFR
phosphorylation. Interestingly, however, the levels of p-EGFR as
well as total EGFR in PANC-1 cells were significantly decreased
after exposure to YM155 in the presence of EGF (Fig. 3A). These
results suggest that YM155 reduced p-EGFR levels via a decrease
in EGFR levels. Cetuximab, used as a positive control, also
decreased p-EGFR in the presence of EGF. A further analysis of
the effects of YM155 on EGFR expression in various cancer cell
lines showed that YM155 induced a concentration-dependent
decrease in EGFR levels in pancreatic (PANC-1, MIAPaCa-2, and
BxPC-3), colorectal (HCT116), prostate (PC3), and lung (H460)
cancer cell lines; similar effects were observed in KATOIII gastric
cancer cells but not in MKN45 gastric cancer cells (Fig. 3B and
Fig. S5).
We examined the effects of YM155 on survivin and EGFR
localization by examining subcellular fraction levels (Fig. 3C);
YM155 reduced survivin levels in both cytoplasmic and nuclear
fractions of PANC-1 cells. EGFR levels were reduced in the
Table 1. YM155 IC50 values in pancreatic cancer cell line.
Cell line YM155 (IC50, nM)
PANC-1 3.69
MIAPaCa-2 29.36
BxPC-3 30.26
Pancreatic cancer cell lines were treated with 10
25–10
1 mM YM155 for 48 hours.
doi:10.1371/journal.pone.0038625.t001
Effects of YM155 on EGFR Expression
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fraction. The nuclear EGFR accumulation induced by 10 nM
YM155 was confirmed by confocal microscopy (Fig. 3D). Because
YM155 (10 nM) had no effect on EGFR levels in total lysates, this
condition may reflect nuclear translocation of EGFR. Collectively,
these data indicate that YM155 reduces the levels of cytoplasmic
and nuclear survivin, and suggest that YM155 promotes EGFR
nuclear translocation.
YM155, which inhibits survivin promoter activity, induces
degradation of EGFR, XIAP, and survivin
To determine whether EGFR is the target of YM155 action, we
examined the effect of YM155 on PANC-1 cell viability after
siRNA-mediated knockdown of EGFR (Fig. S6A). Western
blotting revealed that siSurvivin and siEGFR effectively knocked
down survivin and EGFR, respectively, as shown by Western
blotting, and the percentages of viable cells were approximately
66% and 75%, respectively. The addition of YM155 reduced cell
viability in survivin- or EGFR-knockdown cells to a degree similar
to that observed in control cells transfected with scrambled siRNA.
YM155 acts as a transcriptional inhibitor of survivin, reducing
survivin promoter activity in a concentration-dependent manner
in PANC-1 cells (Fig. S6B). Because of this inhibition of survivin
transcription, YM155 action may be little affected by knockdown
of survivin. By extension, the similar reductions in cell viability by
YM155 observed in EGFR-knockdown and control (scrambled
siRNA) cells may be due to a reduction in survivin level by
YM155.
To determine whether the decreased level of EGFR after
YM155 treatment was due to decreased production or increased
degradation, we analyzed transcript levels using real-time RT-
PCR (Fig. 4A) and assessed the effect of YM155 on protein
degradation using the protein synthesis inhibitor cyclohexamide
(Fig. 4B) in PANC-1 cells. As expected based on its inhibitory
effect on the survivin promoter, YM155 decreased survivin
transcript levels. However, XIAP transcript levels were increased,
an effect that may be a compensatory response to the decrease in
XIAP protein levels. Namely, to protect themselves from
apoptosis, cells might upregulate XIAP, another IAP protein,
when survivin expression is decreased, but the degradation of
XIAP protein by YM155 might result in increased XIAP
transcription as a compensatory mechanism. EGFR transcript
levels were increased by 10 nM YM155 but were decreased by
100 nM YM155. An analysis of changes in protein levels over time
in the absence of protein synthesis (i.e., in the presence of
cycloheximide) showed that survivin, EGFR, and XIAP were
degraded more rapidly in PANC-1 cells treated with YM155 than
in control (cyclohexamide-only) cells. The effects of 100 nM
YM155 on the expression of survivin, EGFR, and XIAP in the
PANC-1 cells over time were investigated (Fig. S7). The 8 h
Figure 1. YM155 affects the expression of XIAP as well as survivin in pancreatic cancer cell lines, and inhibits tumor growth in
MIAPaCa-2 xenograft tumor models. A, Concentration-dependent effects of a 24-hour treatment with YM155 on the expression of survivin and
XIAP in PANC-1, MIAPaCa-2, and BxPC-3 cells were determined by Western blotting. B, The effect of YM155 on the expression of XIAP was compared
with that of survivin knockdown by Western blotting. PANC-1 cells were treated with YM155 for 24 hours or transfected with 40 nM siRNA (siSurvivin,
siXIAP, and scrambled siRNA) for 48 hours. *, nonspecific. C, Concentration-dependent effects of YM155 on the expression of anti-apoptotic (Bcl-xL
and Mcl-1) and pro-apoptotic (Bid and Bad) proteins were examined in PANC-1, MIAPaCa-2, and BxPC-3 cells.
doi:10.1371/journal.pone.0038625.g001
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survivin could be a trigger for subsequent apoptosis. Collectively,
these analyses show that YM155 decreased the production of
survivin and EGFR (high dose, 100 nM) and enhanced the
degradation of survivin, XIAP, and EGFR.
YM155 induces EGFR phosphorylation, and
ubiquitination of EGFR
To determine whether YM155 effects on EGFR, XIAP, and
survivin degradation were proteasome-, lysosome-, or caspase-
dependent, we performed Western blotting in PANC-1 cells after
treating with the proteasome inhibitor MG132, the lysosome
inhibitor chloroquine, or the caspase inhibitor Z-VAD-fmk
(Fig. 5A). Addition of chloroquine to YM155-treated PANC-1
cells blunted the decrease in EGFR, XIAP, and survivin levels,
whereas MG132 and Z-VAD-fmk were ineffective, suggesting that
the shorter half-life of these proteins in the presence of YM155 was
related to enhanced lysosomal degradation. Similar results were
observed in MIAPaCa-2 cells (Fig. S8). We next determined
whether YM155-induced, lysosome-dependent degradation was
associated with ubiquitination of EGFR, XIAP, and survivin
(Fig. 5B). Immunoprecipitation experiments revealed a clear
increase in ubiquitinated EGFR after treatment with YM155
(100 nM) for 6 hours, and a modest increase in survivin and XIAP
ubiquitination. Therefore, YM155 induces ubiquitination of
EGFR, survivin, and XIAP.
The Y1045-phosphorylated form of EGFR is known to interact
with the E3 ubiquitin-protein ligase c-Cbl, which targets EGFR to
the lysosome for subsequent degradation [24]. Because YM155
induced EGFR ubiquitination, we examined the phosphorylation
of EGFR as a function of time after treatment with YM155 by
probing for pY1045-EGFR by Western blotting (Fig. 5C). These
experiments showed a clear decrease in pY1045-EGFR after
exposure to YM155 for 105 minutes or more. These results
suggest that YM155 modulates Y1045-phosporylation of EGFR.
YM155 exhibited anti-tumor effects against pancreatic
cancer in vivo
To evaluate the anti-tumor effects of YM155 on pancreatic
cancer in vivo, we employed a MIAPaCa-2 pancreatic cell line
xenograft tumor model, measuring tumor volume and body
weight (Fig. 6A and 6B). In MIAPaCa-2 xenografts, tumor growth
was inhibited by 77.1% on day 31 after treatment with continuous
infusion of YM155 (p,0.001, YM155 vs. vehicle). Body weight
was not significantly different between untreated and YM155-
treated groups. YM155-treated group on day 31 had smaller
tumor weights than the vehicle-treated animals (Fig. 6C). YM155
induced the downregulation of EGFR, survivin, and XIAP
expressions in xenograft tumors (Fig. 6D). These results indicate
that YM155 exerts a significant anti-tumor effect against
pancreatic cancer in vivo.
Discussion
In the present study, we investigated the effects of the survivin
inhibitor YM155 on survivin, XIAP, and EGFR expression in
pancreatic cancer cell lines. Our data show that YM155 affects the
expression of both survivin and EGFR and thereby reduces
survival. Although previous studies have suggested that YM155
specifically blocks survivin expression in prostate cancer cells and
non-small cell lung cancer (NSCLC) cells without affecting other
proteins [9,16], our data from pancreatic and gastric cancer cells
except MKN45 cells suggest otherwise. However, like its effects in
prostate cancer or NSCLC cells, YM155 effects on XIAP
expression in MKN45 cells were almost not detected. Such cell-
type differential expression of some proteins might reflect cell-line
specific responses of pancreatic or gastric cancer cells to YM155.
In line with previous observations, we found that PANC-1 cells
were the most susceptible to YM155 among the pancreatic cancer
cell lines [6]. PANC-1 cells are known to express higher survivin
mRNA levels than the other two pancreatic cancer cell lines [25].
Buck et al. reported that EGFR expression level is higher in
PANC-1 cells than in MiaPaCa-2 cells [25]. PANC-1 cells
expressing high levels of total and activated AKT have been
reported to exhibit significant cell cycle arrest and apoptosis when
Figure 2. YM155 induces downregulation of PI3K, p-ERK, and
p-STAT3 in PANC-1 cells. A, Levels of PI3K and survivin were
analyzed by Western blotting after treating with YM155 or 30 mM
LY294002 (control) for 24 hours, and 48 hours after transfection with
40 nM siRNA. B, Levels of phosphorylated ERK and expression of
survivin were determined by Western blotting after treating for
24 hours with YM155 or 500 ng of AZD6244, and 48 hours after
transfection of 40 nM siRNA. C, Levels of phosphorylated STAT3 and
expression of survivin were analyzed by Western blotting after a 24-
hours treatment with YM155 and 48 hours after transfection of 40 nM
siRNA.
doi:10.1371/journal.pone.0038625.g002
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pancreatic cancer cell lines [26,27]. PI3K/AKT is regulated by
EGFR [28]. Therefore, the effect of YM155 on EGFR in PANC-1
cells might be associated with AKT. In addition, the high
expression of survivin and EGFR might be cytoprotective and
correlate with YM155 susceptibility. However, further study is
needed to investigate whether susceptibility of cells to YM155 is
associated with cell-line specific alterations in genes such as EGFR
or survivin. In this study, we have shown that YM155 inhibits
tumor growth in MIAPaCa-2 xenografts Therefore, the combi-
nation of YM155 with gemcitabine is also worthy of investigation
in pancreatic cancer.
YM155 is currently undergoing clinical trials [29]. Phase II
trials of YM155 suggested the activity and tolerability in patients
with melanoma and advanced refractory non-small cell lung
cancer [30,31]. The YM155 doses tested in the preclinical stages
through the determination of the maximum tolerated dose (MTD)
or pharmacokinetics studies are applicable to the clinical settings.
A clinical trial can be designed on the basis of the in vitro and in vivo
efficacy of YM155. Based on our preclinical data, YM155 is worth
investigating further in patients with pancreatic cancer.
In our study, YM155 did not change Bcl-xL or Mcl-1 levels.
The results for Bcl-xL were in line with previous observations [9],
whereas those for Mcl-1 were in contrast with those of a previous
report [32]. Tang et al. reported that YM155 downregulates Mcl-
1 in various cancer cell types, but not in pancreatic cancer cells.
This might reflect the cell line-specific responses of pancreatic
cancer cells to YM155. While YM155 induced a concentration-
dependent decrease in Bid, p-Bad, and Bad levels in most
pancreatic cancer cell lines, Bid was unaffected in BxPC-3 cells.
These results indicate that YM155 affects apoptotic proteins levels,
a result that contrasts with previous reports [9].
Previous study showed that a phosphorylation of EGFR was
induced by ionizing radiation in a ligand-independent manner and
ionizing radiation or cisplatin without EGF induced EGFR
transport into the nucleus [33]. They showed that the mechanism
for radiation-induced EGFR import into the nucleus was
associated with a karyopherin a. However, we do not know the
exact mechanism of nuclear translocation of EGFR by YM155
without EGF yet. Thus, further studies are needed to find out the
mechanism by YM155 in nuclear translocation of EGFR. Liccardi
et al. reported that nuclear translocation of EGFR is important in
modulating the repair of DNA damage following chemotherapy
[34]. In this study, 10 nM YM155 induced nuclear translocation
of EGFR and increased EGFR transcript levels. EGFR translo-
cates to the nucleus, where EGFR might activate genes associated
with repair as a transcription factor [35]. However, higher
concentrations of YM155 (100 nM) reduced EGFR transcript
levels and enhanced EGFR degradation. Therefore, increased
transcription and translocation of EGFR at low concentrations
(10 nM) of YM155 might protect cells from apoptosis, whereas
high concentrations (100 nM) decrease cell survival by reducing
EGFR transcription and increasing EGFR degradation.
Levkowitz et al. reported that binding of EGF to EGFR causes
EGFR degradation through binding with c-Cbl at the pY1045-
EGFR [36]. Ahsan et al. reported EGFR phosphorylation,
ubiquitination and degradation in cisplatin-induced cytotoxicity
[37]. Pangbum et al reported that sulindac metabolite also induces
the ubiquitination of EGFR [38]. Similarly, we found that EGFR
phosphorylation, and EGFR ubiquitination and degradation after
treatment with YM155 were induced. However, additional
research is needed to investigate E3 ubiquitin ligase to YM155.
XIAP has been reported to induce the downregulation of
survivin through XAF1 (XIAP associated factor 1) [39]. XIAP has
also been identified as a cofactor of survivin in the inhibition of
Figure 3. YM155 downregulates EGFR in pancreatic cancer cell lines. A, PANC-1 cells were stimulated with 100 ng/ml EGF for 10 minutes
before incubating with or without YM155 for 6 hours. Cetuximab (CTX; 100 ng/ml for 1 hour) was used as a control. Levels of phosphorylated (Y1068)
EGFR and total EGFR were analyzed by Western blotting. B, YM155 diminished the expression of EGFR in a concentration-dependent manner in
PANC-1, MIAPaCa-2 (cropped blots; full-length blots are presented in Fig. S5A), and BxPC-3 cells. The ratio of EGFR:actin expression compared with
the control is shown for each lane (using Multi-Gauge v2.3 software). C, Survivin and EGFR expression were detected in subcellular fractions of PANC-
1 cells by Western blotting. Cytoplasmic (cyto) and nuclear (nu) fractions were isolated after exposure to YM155 for 24 hours. Aldolase (cytoplasmic)
and H3 (nuclear) served as markers for the purity of subcellular fractions. Total lysates (total) were analyzed concurrently. D, YM155 (10 nM) induced
the nuclear EGFR accumulation. PANC-1 cells were stained with anti-EGFR, anti-Alexa Fluor 488, and DAPI after the YM155 treatment. Scale bars:
10 mm.
doi:10.1371/journal.pone.0038625.g003
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apoptotic stimuli interacts with XIAP through an XIAP-binding
site corresponding to Lys15-Met38, resulting in increased XIAP
stability against ubiquitination/proteasomal degradation and
inhibition of apoptosis [41,42]. Phosphorylation of survivin in
the cytoplasm inhibits the assembly of the survivin–XIAP
complex, abolishing its anti-apoptotic function [41]. Our results
showed that the effect of YM155 on XIAP expression differed in
the context of survivin knockdown. YM155 induced an increase in
XIAP transcript levels and promoted XIAP protein degradation.
YM155 decreased the interaction of survivin with XIAP, slightly
enhanced ubiquitination of XIAP, and induced lysosomal
degradation of XIAP. Therefore, YM155 affects the degradation
of XIAP as well as survivin, and interferes with the assembly of the
survivin–XIAP complex. The YM155-induced decrease in XIAP
levels is unlikely due to a reduction in survivin levels. In this study,
we did not examine phosphorylation of survivin by YM155 or
investigate other factors that might affect the survivin–XIAP
complex. Accordingly, additional in-depth mechanistic studies on
YM155 modulation of XIAP should be performed.
In conclusion, we found that YM155, known as a survivin
inhibitor, promotes downregulation of PI3K, p-ERK, and p-
STAT3 through degradation of EGFR in pancreatic cancer cells.
Our data suggest that YM155 has therapeutic potential in
pancreatic cancer and provide support for clinical trials of
YM155 in this context.
Materials and Methods
Cell lines, compounds, plasmid, and antibodies
The human pancreatic cancer cell lines PANC-1, MIAPaCa-2,
and BxPC-3 were obtained from the American Type Culture
Collection (Manassas, VA, USAA). YM155 was obtained from
Hanmi Pharmaceuticals (Seoul, Korea). Other reagents used
include LY294002 (Calbiochem, Darmstadt, Germany),
AZD6244 (Chemizon Korea), MG132 (Calbiochem), chloroquine
(Sigma-Aldrich, St Louis, MO), Z-VAD-fmk (R&D Systems, MN,
USA), cycloheximide (Sigma-Aldrich), epidermal growth factor
(EGF; Daewoong Pharmaceuticals, Korea), and cetuximab (Merck
Korea). Primary antibodies against the following proteins were
used for Western blot analyses: survivin (Abcam, Cambridge, MA,
USA); XIAP (BD Biosciences, San Jose, CA, USA); ubiquitin and
b-actin (Santa Cruz Biotechnology, Santa Cruz, CA); EGFR,
phospho (p)-EGFR (Y1068, Y1045), Bcl-xL, Mcl-1, Bid, p-Bad
(S112), Bad, PI3K, ERK, p-ERK (T202/Y204), STAT3, p-
STAT3 (Y705), aldolase, and H3 (Cell Signaling, Danvers, MA,
USA). Immunoreactive proteins were detected using species-
appropriate horseradish peroxidase-conjugated secondary anti-
Figure 4. YM155 increases the degradation of survivin, EGFR, and XIAP in PANC-1 cells. A, After treatment of PANC-1 cells with YM155 for
24 hours, survivin, EGFR, and XIAP mRNA levels were determined using real-time RT-PCR. B, Survivin, EGFR, and XIAP levels in PANC-1 cells after
treatment with 50 mg/ml cycloheximide (CHX) in the absence or presence of 100 nM YM155 for the indicated periods were examined by Western
blotting. The ratio of survivin, EGFR, or XIAP:actin expression compared with the control is shown for each lane. *, nonspecific.
doi:10.1371/journal.pone.0038625.g004
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S1.
Cell viability assay and siRNA transfection
Cell viability was determined using a Cell Counting Kit-8
(Dojindo Laboratories, Kumamoto, Japan), according to the
manufacturer’s instructions. Three independent experiments were
performed in duplicate. Fifty percent inhibitory concentrations
(IC50s) were determined using GraphPad Prism (Graphpad
Software Inc., San Diego). siRNA against survivin (siSurvivin,
59-AAG GCU GGG AGC CAG AUG ACG UU-39 [sense]; 59-
CGU CAU CUG GCU CCC AGC CUU UU-39 [antisense]),
XIAP (siXIAP, 59-AAG UGG UAG UCC UGU UUC AGC U-39
[sense]; 59-GCU GAA ACA GGA CUA CCA CUU UU-39
[antisense]), EGFR (siEGFR, 59-AAG AUC AUA AUU CCU
CUG CUU-39 [sense]; 59-GCA GAG GAA UUA UGA UCU
UUU-39 [antisense]), and scrambled siRNA (control, non-target-
ing siRNA) were obtained from Thermo Scientific Dharmacon
(Lafayette, CO, USA). siRNA transfections were carried out using
Lipofectamine RNAiMAX (Invitrogen, San Diego, CA, USA),
according to the manufacturer’s protocols.
Real-time reverse transcription-polymerase chain
reaction (RT-PCR) analysis
Total RNA from PANC-1 cells treated with YM155 (0, 10,
100 nM) for 24 hours was isolated using TRIzol reagent
(Invitrogen), and cDNA was synthesized from total RNA using
the SuperScript III First-Strand Synthesis System (Invitrogen).
Quantitative PCR was then performed on a LightCycler 480
instrument (Roche, Germany) using SYBR Green I Master
(Roche) and the following primers (Xenotech, Daejeon, Korea):
survivin, 59-ATT CGT CCG GTT GCG CTT TCC-39 (forward)
and 59-CAC GGC GCA CTT TCT TCG CAG-39 (reverse);
EGFR, 59-CTC AGC CAC CCA TAT GTA CC-39 (forward)
and 59-CGT CCA TGT CTT CTT CAT CC-39 (reverse); XIAP,
59-GAC AGT ATG CAA GAT GAG TCA AGT CA-39 (forward)
and 59-GCA AAG CTT CTC CTC TTG CAG-39 (reverse); and
GAPDH, 59-GAG TCA ACG GAT TTG GTC GT-39 (forward)
and 59-TTG ATT TTG GAG GGA TCT CG-39 (reverse). A
melting curve analysis was performed on all PCR products to
confirm the specificity of amplification reactions.
Immunoprecipitation and subcellular fractionation
Following treatment of PANC-1 cells with 100 nM YM155,
whole-cell lysates were prepared in lysis buffer (20 mM Tris,
150 mM sodium chloride, 1 mM ethylenediaminetetraacetic acid,
1 mM ethylene glycol tetraacetic acid, 2.5 mM sodium pyrophos-
phate, 1 mM b-glycerol phosphate, 0.5% Triton X-100) contain-
ing protease inhibitor cocktail (Roche Germany) and phosphatase
inhibitor cocktail (Sigma-Aldrich). For immunoprecipitations, pre-
cleared cell lysates (500 mg protein) were incubated overnight at
4uC with primary antibodies against survivin, EGFR, or XIAP
(Abnova, Fig. 5B) precoupled to protein G sepharose (GE
Healthcare, Piscataway, NJ). After five washes with washing
buffer (10 mM Tris-Cl pH 7.4, 200 mM sodium chloride,
2.5 mM MgCl2, 0.1% Triton X-100, protease inhibitor cocktail),
immunocomplexes were examined by Western blotting using
antibodies indicated in the text. Nuclear and cytoplasmic extracts
were prepared using a NE-PER Nuclear and Cytoplasmic
Extraction Kit (Pierce, Rockford, IL, USA), according to
manufacturer’s protocols.
Figure 5. YM155 induces EGFR phosphorylation, EGFR ubiquitination and degradation of EGFR via the lysosome in PANC-1 cells. A,
YM155 induced lysosomal degradation of EGFR, XIAP, and survivin in PANC-1 cells. PANC-1 cells were treated with 100 nM YM155 (YM), 10 mM MG-
132 (MG), 50 mM chloroquine (CQ), or 30 mM Z-VAD-fmk (Z-VAD) without or with YM155 for 24 hours. The expression ratios of EGFR, XIAP, or survivin
to actin compared with the control are shown for each lane. ctrl, control; M+Y, MG-132+YM155; C+Y, chloroquine+YM155; Z+Y, Z-VAD-fmk+YM155. B,
PANC-1 cells treated with 100 nM YM155 for 6 hours were immunoprecipitated (IP) with antibodies against EGFR, survivin or XIAP, and analyzed by
Western blotting for ubiquitin. C, The time-course of EGFR phosphorylation at Y1045 in PANC-1 cells after treatment with YM155 (100 nM) is shown.
doi:10.1371/journal.pone.0038625.g005
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PANC-1 cells treated for 24 hours with YM155 were fixed with
a 4% paraformaldehyde solution and permeabilized with 0.2%
Triton X-100 in PBS. And then, cells were blocked with 10% fetal
bovine serum (FBS) and incubated at 4uC for 18 hours with anti-
EGFR (Calbiochem, San Diego, CA, USA) in 1.5% FBS in PBS.
Alexa Fluor 488 anti-mouse (Molecular Probes and Invitrogen)
was incubated at room temperature for 1 hour. Finally, cells were
stained with DAPI (Invitrogen) for 5 min and mounted with
fluorescence mounting medium (Dako, Carpinteria, CA, USA).
Cells were visualized by confocal microscopy (Leica, Wetzlar,
Germany).
Xenograft model
Five-week-old female athymic nude (nu/nu) mice were
purchased from Japan SLC Inc. (Shizuoka, Japan). The study
was approved by our Institutionl Animal Care and Use
Committee (IACUC). Tumors were established by injecting
5610
6 MIAPaCa-2 cells subcutaneously into the left flank of
mice. When subcutaneous tumors reached a size of 100 mm
3 (day
0), xenografted animals were randomly allocated into vehicle and
YM155 (50 mg/kg) groups. YM155 was subcutaneously admin-
istered as a 3-day continuous infusion per week for 2 weeks using
an implanted microosmotic pump (Alzet model 1003D, Durect)
[9]. Tumors were measured twice weekly with calipers, and
volume (mm
3), calculated as (length6width
2)/2, was determined.
Body weights were also monitored.
Histopathology and immunohistochemistry
Tumor samples were fixed with 10% formalin and embedded in
paraffin, and 4 mm sections were prepared. 4 mm sections were
stained with hematoxylin and eosin (H&E). The overexpressions of
EGFR, survivin, or XIAP were examined immunohistochemically
in tissues from mice bearing MIAPaCa-2 xenograft tumors.
Immunohistochemical analyses were performed as previously
described [15].
Statistical Analysis
The data obtained are expressed as means 6 SEMs. Differences
between tests groups were analyzed by Mann-Whitney tests using
GraphPad InStat (Graphpad Software). P-values ,0.05 were
considered statistically significant.
Supporting Information
Figure S1 YM155 affects expression of XIAP as well as
survivin in gastric cancer cell lines. Concentration-de-
pendent effects of 24-hour treatment with YM155 on the
expression of survivin and XIAP in KATOIII and MKN45 cells
were determined by Western blotting.
(TIF)
Figure S2 YM155 has little effect on the expression of
cIAP1/2 in PANC-1, MIAPaCa-2, and BxPC-3 cells. Cells
were treated with different concentrations of YM155 for 24 hours.
(TIF)
Figure 6. YM155 exhibits anti-tumor effects against pancreatic cancer in vivo. Effects of YM155 on tumor growth (A) and body weight (B) in
vivo were evaluated in MIAPaCa-2 xenografts (vehicle, n=6; YM155, n=8). Tumor volume was determined at the indicated times after the onset of
treatment. YM155 was administered at dose of 50 mg/kg. The in vivo experimental schedule of YM155 is indicated at the bottom of each graph. Day
0 indicates the time at which subcutaneous tumors reached a size of 100 mm
3 and administration of YM155 was started. Statistical analyses of the
effects of YM155 on tumor size were performed using Mann-Whitney tests (*p,0.05, **p,0.01, ***p,0.001, YM155 vs. vehicle). C, Average tumor
sizes are depicted for each group on day 31. D, Immunohistochemical analyses in xenograft tumors on day 31 after the YM155 treatment were
performed using antibodies against EGFR, survivin, and XIAP and stained with H&E.
doi:10.1371/journal.pone.0038625.g006
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YM155. Following treatment of PANC-1 cells with 100 nM
YM155 for 6 hours, cell lysates were immunoprecipitated with an
anti-survivin antibody and immunoprecipitates were probed for
XIAP and survivin by Western blotting. The levels of survivin and
XIAP in YM155-treated PANC-1 cell lysates are shown. The ratio
of XIAP:survivin expression compared to control (0 nM YM155)
is shown for each lane (using Multi-Gauge v2.3 software). NC,
negative control (no lysates).
(TIF)
Figure S4 YM155 decreases the expression of PI3K
family members and p-Akt levels in pancreatic cancer
cell lines. Western blotting was performed after treatment of
three pancreatic cancer cell lines with different concentrations of
YM155 for 24 hours.
(TIF)
Figure S5 YM155 downregulates expression of EGFR in
various cancer cell lines. A, Full-length blots showing
concentration-dependent effects of YM155 on EGFR expression
in MIAPaCa-2 are presented. B. YM155 diminished the
expression of EGFR in a concentration-dependent manner in
HCT116 and KATOIII cells, but not in MKN45 cells. In PC3
prostate cancer cells (C) and H460 lung cancer cells (D), YM155
decreased the expression of EGFR in a concentration-dependent
manner, but did not change the expression of XIAP as in previous
reports [9,16].
(TIF)
Figure S6 YM155 decreases survivin transcriptional
activity in PANC-1 cells. A, The viability of PANC-1 cells
was examined after transfection with siSurvivin, siEGFR, or
scrambled siRNA (40 nM) for 48 hours followed by incubation
without or with YM155 (10 nM) for 24 hours. B, YM155 induces
a concentration-dependent decrease in survivin transcriptional
activity in PANC-1 cells, measured using a survivin gene
promoter-driven luciferase reporter.
(TIF)
Figure S7 Treatment of YM155 for 8 hours significantly
reduces survivin levels. Effects of 100 nM YM155 on the
expression of survivin, EGFR, and XIAP in PANC-1 cells
according to time were determined by Western blotting.
(TIF)
Figure S8 YM155 induces the lysosomal degradation of
EGFR, XIAP, and survivin in MIAPaCa-2 cells. MIAPaCa-
2 cells were treated with 100 nM YM155 (YM), 10 mM MG-132
(MG), 50 mM chloroquine (CQ), or 30 mM Z-VAD-fmk (Z-VAD)
without or with YM155 for 24 hours. ctrl, control; M+Y, MG-
132+YM155; C+Y, chloroquine+YM155; Z+Y, Z-VAD-
fmk+YM155.
(TIF)
Materials and Methods S1 Cell lines, compounds,
plasmid, and antibodies. Transfection and luciferase
reporter assay.
(DOC)
Table S1 YM155 IC50 values in gastric and colorectal
cancer cell lines.
(DOC)
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